Compare IGIC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | PHAT |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.2M | 894.0M |
| IPO Year | 2019 | 2019 |
| Metric | IGIC | PHAT |
|---|---|---|
| Price | $26.27 | $12.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $19.83 |
| AVG Volume (30 Days) | 59.0K | ★ 987.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $0.13 | $93.04 |
| Revenue Next Year | $2.54 | $58.91 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $20.82 | $2.21 |
| 52 Week High | $26.40 | $18.31 |
| Indicator | IGIC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 69.97 | 64.20 |
| Support Level | $23.20 | $12.31 |
| Resistance Level | N/A | $12.88 |
| Average True Range (ATR) | 0.67 | 0.64 |
| MACD | 0.30 | 0.27 |
| Stochastic Oscillator | 99.28 | 80.87 |
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.